Durham, NC—October 12, 2018— NeuroCog Trials announced today that they are changing their name to VeraSci and have rebranded all of their materials and website to better represent their current position as comprehensive collaborative partners in scientific discovery....read more
DURHAM, NC, July 9, 2018– Specializing in Alzheimer’s Disease (AD) and other neurological and age-related disorders, Dr. Kathleen Anne Welsh-Bohmer, Professor of Psychiatry and Neurology at Duke University, joins the accomplished scientific team at NeuroCog Trials...read more
NeuroCog Trials Awarded NIH Grant to Validate Performance-based Measure of Functioning in MCI & Alzheimer’s Disease
Innovative technology answers the call for improved functional capacity measurements in cognitive disorders Durham, North Carolina, October 30, 2017 -- NeuroCog Trials, Inc. (NCT), the premier global cognition and clinical assessment consulting and technology company,...read more
Experienced pharmacologist, clinical scientist and senior regulatory leader brings new capabilities and expertise to growing clinical trials technology and service provider DURHAM, NORTH CAROLINA, September 18, 2017 – NeuroCog Trials (NCT), a clinical technology and...read more
DURHAM, NORTH CAROLINA, May 19, 2017 NCT Linguistics, a leading global provider of translation, interpretation, and training services, was honored to sponsor Triangle Biotech Tuesday in Research Triangle Park on Tuesday, May 9, 2017. Triangle Biotech Tuesday is a...read more
NCT Linguistics and NeuroCog Trials Expand Workforce, Office Space At Durham Headquarters – Press Release
DURHAM, NC, Nov. 30, 2016 — NeuroCog Trials, the leading cognitive services provider for the clinical trials industry, today announced that it is significantly expanding its presence at its headquarters in Durham. Construction is currently underway to give NeuroCog...read more
NCT Linguistics becomes the exclusive provider of translation services for Percept Research DURHAM, NORTH CAROLINA, October 10, 2016 – NCT Linguistics, the boutique language solutions provider, today announced that it has signed an exclusive agreement with Percept...read more
NeuroCog Trials welcomes the outcome of the FDA Psychopharmacologic Drug Advisory Committee meeting that cognitive dysfunction in Major Depressive Disorder (MDD) represents an appropriate drug development target. The issue was discussed at the meeting on February 3rd...read more
NeuroCog Trials, Inc. announces work supporting a major pharmaceutical company clinical trial to assess performance based skills assessment in patients with major depression.
Durham, NC—July 1, 2014— NeuroCog Trials, Inc. announces that it has begun work supporting a major pharmaceutical company clinical trial to assess performance- based skills assessment in patients with major depression. The trial will examine the effects of active drug...read more
NeuroCog Trials, Inc. announces a new method established for reviewing administration procedures and data collection for the Alzheimer’s Disease Assessment Scale (ADAS-Cog).
NeuroCog Trials, Inc. announces that a new method has been established for reviewing administration procedures and data collection for the Alzheimer’s Disease Assessment Scale (ADAS-Cog). This method will be utilized by a large pharmaceutical company for a new...read more